Irene Olivera
Overview
Explore the profile of Irene Olivera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Teijeira A, Garasa S, Luri-Rey C, de Andrea C, Gato M, Molina C, et al.
Cancer Res
. 2022 Sep;
82(23):4373-4385.
PMID: 36130020
Significance: These findings reveal the intratumoral behavior of cDC1 dendritic cells in transgenic mouse models and demonstrate that the efficacy of immunotherapy regimens is precluded by elimination of these cells.
12.
Olivera I, Sanz-Pamplona R, Bolanos E, Rodriguez I, Etxeberria I, Cirella A, et al.
Cancer Discov
. 2022 Jun;
12(9):2140-2157.
PMID: 35771565
Significance: IL-8 attracts immunosuppressive protumor myeloid cells to the tumor microenvironment, and IL-8 levels correlate with poor response to checkpoint inhibitors. TNFα and IL-1β are identified as major inducers of...
13.
Cirella A, Luri-Rey C, Di Trani C, Teijeira A, Olivera I, Bolanos E, et al.
Pharmacol Ther
. 2022 Apr;
239:108189.
PMID: 35430292
Interleukin-12 is considered a potent agent to enhance antitumor immune responses. It belongs to a family of heterodimeric cytokines with key roles in the up-regulation and down-regulation of cellular immunity....
14.
Glez-Vaz J, Azpilikueta A, Olivera I, Cirella A, Teijeira A, Ochoa M, et al.
J Immunother Cancer
. 2022 Mar;
10(3).
PMID: 35236742
Background: On the basis of efficacy in mouse tumor models, multiple CD137 (4-1BB) agonist agents are being preclinically and clinically developed. The costimulatory molecule CD137 is inducibly expressed as a...
15.
Teijeira A, Migueliz I, Garasa S, Karanikas V, Luri C, Cirella A, et al.
Theranostics
. 2022 Feb;
12(3):1373-1387.
PMID: 35154495
The CEA-CD3 T cell bispecific antibody cibisatamab (CEA-TCB) is currently undergoing clinical trials. Here we study its performance against three-dimensional tumor organoids in cocultures with T cells as compared to...
16.
Di Trani C, Fernandez-Sendin M, Cirella A, Segues A, Olivera I, Bolanos E, et al.
Expert Opin Drug Discov
. 2021 Sep;
17(1):41-53.
PMID: 34496689
Introduction: Immune checkpoint inhibitors and adoptive T-cell therapy based on chimeric antigen receptors are the spearhead strategies to exploit the immune system to fight cancer. To take advantage of the...
17.
Etxeberria I, Bolanos E, Teijeira A, Garasa S, Yanguas A, Azpilikueta A, et al.
Proc Natl Acad Sci U S A
. 2021 Jun;
118(26).
PMID: 34172583
Costimulation via CD137 (4-1BB) enhances antitumor immunity mediated by cytotoxic T lymphocytes. Anti-CD137 agonist antibodies elicit mild liver inflammation in mice, and the maximum tolerated dose of Urelumab, an anti-human...
18.
Teijeira A, Garasa S, Ochoa M, Cirella A, Olivera I, Glez-Vaz J, et al.
Eur J Immunol
. 2021 May;
51(9):2274-2280.
PMID: 33963542
In humans, IL-8 (CXCL8) is a key chemokine for chemotaxis of polymorphonuclear leukocytes and monocytes/macrophages when acting on CXCR1 and CXCR2. CXCL8 activity on neutrophils includes chemotaxis and eliciting the...
19.
Teijeira A, Garasa S, Ochoa M, Villalba M, Olivera I, Cirella A, et al.
Clin Cancer Res
. 2020 Dec;
27(9):2383-2393.
PMID: 33376096
One of the most important mechanisms by which cancer fosters its own development is the generation of an immune microenvironment that inhibits or impairs antitumor immune responses. A cancer permissive...
20.
Etxeberria I, Olivera I, Bolanos E, Cirella A, Teijeira A, Berraondo P, et al.
Cell Mol Immunol
. 2020 May;
17(6):576-586.
PMID: 32433539
Gene engineering and combinatorial approaches with other cancer immunotherapy agents may confer capabilities enabling full tumor rejection by adoptive T cell therapy (ACT). The provision of proper costimulatory receptor activity...